MARKET

NSPR

NSPR

Inspiremd
NASDAQ
2.930
+0.060
+2.09%
Opening 12:23 02/19 EST
OPEN
3.000
PREV CLOSE
2.870
HIGH
3.100
LOW
2.930
VOLUME
22.90K
TURNOVER
--
52 WEEK HIGH
3.420
52 WEEK LOW
1.810
MARKET CAP
76.43M
P/E (TTM)
-3.9088
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NSPR last week (0210-0214)?
Weekly Report · 2d ago
InspireMD participates in a conference call with Lake Street
TipRanks · 4d ago
InspireMD (NSPR) Receives a Buy from Lake Street
TipRanks · 6d ago
BRIEF-InspireMD And NAMSA To Partner On CGuardians II Pivotal Clinical Trial Of The CGuard Prime 80 Cm Carotid Stent System For Use In TCAR Procedures
Reuters · 6d ago
InspireMD, NAMSA partner on CGUARDIANS II trial of CGuard Prime
TipRanks · 6d ago
Weekly Report: what happened at NSPR last week (0203-0207)?
Weekly Report · 02/10 10:27
InspireMD announces inducement grants under Nasdaq listing rule
TipRanks · 02/04 12:11
INSPIREMD ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 02/04 12:00
More
About NSPR
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Webull offers InspireMD Inc stock information, including NASDAQ: NSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NSPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NSPR stock methods without spending real money on the virtual paper trading platform.